Update: Arcutis Expects FDA’s Action Letter for Roflumilast SNDA Indicated For AD
Arcutis Biotherapeutics, Inc. announced that the Company has been in communication with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) for adults and children down to the age of 6. The FDA has indicated that they […]